- News Releases
-
- Nov. 25, 2020 (PDF/30KB)R&D
- Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
-
- Oct. 28, 2020 (PDF/1,170KB)Finances
- Investors Meeting Presentation for Q2 FY2020 (April 1 to September 30, 2020）
-
- Oct. 28, 2020 (PDF/436KB)Finances
- Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2021
Other Notices
-
- Nov. 20, 2020Others
- Posted Factbook 2020 ver.2
-
- Sep. 30, 2020Others
- Posted Integrated Report 2020
-
- Jun. 30, 2020Others
- Posted Factbook 2020
IR Library
-
Continuing to challenge ourselves to support a healthy future for people
-
Aiming to create innovative pharmaceutical products
-
Targeting sustainable growth
-
Leading our global expansion